Influenza A (H1N1) in Rome, Italy in family: three case reports by Lisena, Francesco et al.
BioMed  Central
Page 1 of 4
(page number not for citation purposes)
Cases Journal
Open Access Case Report
Influenza A (H1N1) in Rome, Italy in family: three case reports
Francesco Lisena, Licia Bordi, Fabrizio Carletti, Concetta Castilletti, 
Federica Ferraro, Eleonora Lalle, Simone Lanini, Luca Enrico Ruscitti and 
Francesco Maria Fusco*
Address: Istituto Nazionale per le Malattie Infettive IRCCS Lazzaro Spallanzani - Roma Via Portuense, 292 - 00149 Rome, Italy
Email: Francesco Lisena - lisena@inmi.it; Licia Bordi - lbordi@inmi.it; Fabrizio Carletti - carletti@inmi.it; 
Concetta Castilletti - castilletti@inmi.it; Federica Ferraro - federica.ferraro@inmi.it; Eleonora Lalle - lalle@inmi.it; 
Simone Lanini - lanini@inmi.it; Luca Enrico Ruscitti - lucaenrico.ruscitti@inmi.it; Francesco Maria Fusco* - fusco@inmi.it
* Corresponding author    
Abstract
Introduction: A new Influenza A virus H1N1 appeared in March-April 2009, and thousands of
cases are being reported worldwide. In the initial months, several imported cases were reported
in many European countries, while some countries reported local chains of transmission. We
describe the first cluster of in-country transmission of the new Influenza A H1N1 which occurred
in Italy, involving 3 patients.
Case presentation: Patient 1, a 11-year-old male child developed fever, cough, and general
malaise 4 days after returning from a travel to Mexico. Some days later, the 69-year-old grandfather
(patient 2), who did not travel to Mexico, and the 33-month-old brother (patient 3) of patient 1
developed mild influenza symptoms. PCR tests resulted positive for Influenza A, and sequence
analysis confirmed infection with the Influenza A (H1N1) strain for all three patients. Some
problems were experienced in the administration of chemoprophylaxis and therapy in the patient
3. The chemoprophylaxis policies in other family members are described, too.
Conclusion: Some interesting facts emerge from the analysis of this cluster. The transmission of
Influenza A H1N1 virus seems to be dependent on strict contacts. Patient 2 and patient 3 did not
take the chemoprophylaxis properly. The problems in the administration of chemoprophylaxis and
therapy to patient 3 suggest that in infants specific individual-based strategies for assuring the
correct administration are advisable.
Background
Swine Influenza virus has in the past caused sporadic
infections in humans, causing different clinical pictures
ranging from mild respiratory symptoms to, rarely, severe
diseases with pneumonia and deaths [1]. A new Influenza
A H1N1 virus of swine origin appeared in March-April
2009, and because of its capability to be directly transmit-
ted from human to human, thousands of cases are now
being reported worldwide. In the initial months, in
Europe many imported cases were reported. Sustained
autochthonous transmission firstly appeared in Spain and
United Kingdom [2], while presently local chains of trans-
mission are ongoing in most European countries. Hereby
we describe a familiar cluster involving 3 patients. This is
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the first in-country transmission of the new Influenza A
H1N1 described in Italy.
Case presentation
Patient 1
On May 3, patient 1, a 11-year-old male child presented
for medical evaluation at Admission Department of the
National Institute for Infectious Disease (Istituto Nazion-
ale per le Malattie Infettive, INMI) "Lazzaro Spallanzani",
in Rome, Italy.
He reported abrupt onset of fever, cough, and general
malaise in the night between 2nd and 3rd of May. He had
returned on April 29, with his parents, a sister and a
brother, from Mexico, in the Yucatan area.
At presentation the patient was febrile (38°C), and
reported coryza and bilateral pain in the ear. According to
case definition in use at our Institute the patient was man-
aged as a suspected case of Influenza A H1N1. A nasopha-
ryngeal swab was taken, and a rapid test was positive for
Influenza A. Subsequently, a PCR test was positive for
Influenza A, and sequence analysis confirmed infection
with the new Influenza A (H1N1) strain. A chest X-ray did
not show any evidence of pneumonia. On the same day
therapy with oseltamivir was started, at dosages appropri-
ate for the patient's weight, then the patient was trans-
ferred to a referral paediatric hospital, where he was
isolated. The patient completely recovered in few days,
and was discharged after 7 days of isolation.
Patient 2
On May 5, patient 2, a 69-year-old man, grandfather of
patient 1, referred to INMI Admission Department,
because of onset of fever (37,4°C), the day before, on May
4. At history taking he reported to have had close contact
with his nephew (patient 1).
At the admission visit, general conditions of patient 2
were good, and the patient was already afebrile. The
patient was coughing forcefully, although he reported it
was a usual symptom being a smoker.
The rapid test for Influenza A was negative. Subsequently,
the PCR was reported positive for Influenza A, and
sequence analysis confirmed infection with the same
strain affecting patient 1. Patient 2 refused hospital admis-
sion, then treatment with oseltamivir was started, and the
patient was quarantined at home for 7 days. His general
condition improved, and he did not have fever or other
symptoms thereafter.
Patient 3
On May 6, patient 3, a 33-month-old infant, brother of
patient 1, was accompanied by his father for evaluation to
the referral paediatric hospital where the patient 1 had
been isolated. He also had fever (38,2°C) and coryza, and
the father reported that the infant was irritable and
unwell. A rapid test for Influenza was positive, and the
patient was sent home with advise to take treatment with
oseltamivir. Since May 4, Patient 3 was on chemo-proph-
ylaxis with oseltamivir, but adherence was poor because,
despite the use of the syrup, the child refused to swallow
and spew out the drug.
On May 7, the father and the patient 3 came for medical
examination and advice to INMI. At the admission visit,
only mild coryza was recorded. A second rapid test for
Influenza resulted negative, while the PCR resulted posi-
tive for Influenza A. The switch to therapeutic dosage of
oseltamivir was confirmed, and physicians also suggested
administering the drug with some sweet foods or bever-
ages. In such a way, the patient 3 had therapy regularly,
and no more symptoms were noticed. Sequence analysis
confirmed the infection with the new strain of Influenza
A H1N1 virus.
Other family members
The mother of patients 1 and 3, who gave care to patient
1 during his admission to paediatric hospital, started
prophylaxis with oseltamivir on May 3. The 14-year-old
sister of patients 1 and 3 began the prophylaxis with osel-
tamivir on May 4. The grandmother, who slept together
with patient 1 at the moment of symptoms' onset, and the
father of patients 1 and 3 started prophylaxis on May 5.
None of them developed symptoms.
Laboratory analysis
Rapid Influenza testing at INMI was based on BinaxNOW
Influenza A & B, able to detect and differentiate Influenza
A and B. The test was performed on freshly collected
nasopharyngeal swab samples, immediately upon arrival
to the laboratory.
Nucleic acid extraction: nasopharyngeal swab samples were
extracted with MagMAX TM- 96 viral RNA Isolation Kit
(Ambion, Applied Biosystem), according to manufac-
turer's instructions, using MagMAX TM Express magnetic
particle processor. The efficiency of the extraction was
evaluated using a method previously established in our
laboratory [3].
Molecular testing: the detection of Influenza A was based
on RT-PCR, using a primer set with enhanced sensitivity
for the new Influenza A H1N1 strain, targeting NP
(Nucleo Proteins), established in our laboratory on the
basis of the sequences of swine AH1N1 published on the
GSAID (Global Initiative on Sharing Avian Influenza
Data) Web site. The detailed protocol will be described
elsewhere (Di Caro et al., manuscript in preparation).Cases Journal 2009, 2:9123 http://www.casesjournal.com/content/2/1/9123
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All the RT-PCR reactions were performed using One-Step
RT-PCR Enzyme Mix (Qiagen, Valencia, CA).
Positive results for the new Influenza A H1N1 were con-
firmed by the National Reference Laboratory for Influ-
enza.
The strain identification was based on the sequence anal-
ysis of the amplicon (282 bp), performed with the auto-
mated ABI Prism 3100 instrument, by using BigDye
terminator cycle sequencing kit (Applied Biosystem, War-
rington, UK). The primers used for the sequencing reac-
tion were the same as those used for the RT-PCR. The NP
amplicon sequences of the 3 patients were compared to
GenBank reference sequences by BLAST (Basic Local
Alignment Search Tool) search analysis. In all cases, the
highest hit were new Influenza A H1N1 strains, and Blast
search analysis results indicated 98, 99 and 99% (respec-
tively, for patients 1, 2 and 3) identity over the corre-
sponding stretch of 282 nucleotides sequence of the
California 04/2009 H1N1 isolate from the current out-
break (GenBank accession number FJ969512).
All the NP partial sequences have been submitted to Gen-
Bank, accession numbers FJ985805, GQ132135,
GQ132187.
Conclusion
This report briefly describe the first cluster of in-country
transmission of the new Influenza A H1N1 which
occurred in Italy.
The figure 1 summarized the timeline of this described
cluster. The index patient, patient 1, most probably
acquired the infection during the travel, with his family, in
Mexico. Patient 2 did not visit the endemic areas, and pre-
sumably acquired the infection from the nephew (patient
1), who slept with him during the night when symptoms
had appeared. On the basis of time lapse between return
from Mexico and start of symptoms (8 days), it is likely
that patient 3 also acquired the infection in Italy, follow-
ing close contacts with his brother (patient 1), or, alterna-
tively, from his grandfather (patient 2). Indeed, patients
with the new Influenza A H1N1 are assumed to be shed-
ding virus from one day prior to illness onset until resolu-
tion of symptoms [4]. In the case he acquired the infection
from the grandfather, patient 3 may represent a tertiary
case. Since children are likely to have a social behaviour
prone to cause close contacts with secretions, it is reason-
able that he had had high-risk exposures to the secretions
of the brother or of the grandfather.
Notably, patient 2 and patient 3 did not assume or
assumed not properly the chemoprophylaxis, respec-
tively. The remaining close contacts who assumed chemo-
prophylaxis promptly (the mother and the sister of
patients 1 and 3, who respectively started chemoprophy-
laxis on May 3 and 4), or later (the grandmother and the
father of patients 1 and 3) did not develop any symptoms,
although viral transmission cannot be ruled out in
absence of laboratory tests (i.e. seroconversion).
Timeline of a familiar outbreak of new Influenza A H1N1 in Italy Figure 1
Timeline of a familiar outbreak of new Influenza A H1N1 in Italy.
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R: returning flight from Mexico; SO: symptoms’ onset; SE: symptoms’ end; T: therapy with oseltamivir; C: chemoprophylaxis with oseltamivir. 
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At the beginning of the pandemic, when these patients
were observed, the treatment with oseltamivir (75-mg
capsule twice per day for 5 days for adults, weight-based
for children) or zanamivir (two 5-mg inhalations -10 mg
total - twice per day for 5 days for adults and children
older than 7-year-old) was usually administered to all
patients. For this reason, in the described cluster therapy
has been given also to those patients presenting with mild
symptoms, as patients 2 and 3.
Currently, the use of antiviral therapy is suggested in sus-
pected/probable/confirmed patients, with priority given
to hospitalized patients and patients at higher risk for
influenza complications. Antiviral treatment with zan-
amivir or oseltamivir should be initiated as soon as possi-
ble after the onset of symptoms [5]. Oseltamivir is
administered orally, and zanamivir by inhalation, but the
successful use of intravenous zanamivir in a patient with
severe H1N1 pneumonitis has been recently reported [6]
Chemoprophylaxis with the same drugs (oseltamivir 75-
mg capsule once per day for 10 days for adults, weight-
based for children, and zanamivir, two 5-mg inhalations -
10 mg total - once per day for 10 days in adults and chil-
dren older than 5-year-old) is currently recommended
only to those persons at high risk for complications of
influenza [5]. At the beginning of the pandemic, instead,
chemoprophylaxis was usually suggested to all close con-
tacts of the patients with new Influenza A H1N1.
The management of the infant presents interesting issues:
indeed, in this patient the administration of chemoproph-
ylaxis and therapy required special care. In paediatric
patients, specific individual-based strategies must be
developed in order to assure the regular administration of
oseltamivir.
All described cases were mild, and promptly recovered in
few days. Similar clinical pictures are reported in the vast
majority of other cases in the world.
Our observation also evidences the poor sensitivity of
rapid diagnostic tests for Influenza, as confirmed by a
recent study [7]. In our three confirmed patients, four
rapid tests were performed. It was positive only in patient
1, while resulted negative in patient 2. In patient 3, rapid
test was positive on the day of symptoms' onset, but rap-
idly turned negative on day after.
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